Phosphoinositide-dependent protein kinase-1 (PDK1), the class of serine threonine kinase, is a master regulator of the AGC family of kinases. It is a main component of the PI3K pathway. As it is reported that this pat...Phosphoinositide-dependent protein kinase-1 (PDK1), the class of serine threonine kinase, is a master regulator of the AGC family of kinases. It is a main component of the PI3K pathway. As it is reported that this pathway is most commonly, and this pathway is the most commonly deregulated among many cancers. So designing a selective inhibitor of PDK1 may have the efficacy as an anticancer agent. Herein, we describe our work focused on the structure based on screening of 95% similar analogues of Myricetin deposited in PubChem database as earlier studies have been suggested that myricetin acts as an anti cancer agent. Further molecular docking as well as the in silico ADMET studies are incorporated on these compounds to evaluate the binding and pharmacokinetic properties of these compounds. Due to low oral bioavailability, clinical use of myricetin is limited. Therefore this study is an attempt towards screening of structurally similar better compounds as compare with myricetin which can act as better inhibitor against PDK-1.展开更多
背景:国内外对于3-磷酸肌醇依赖蛋白激酶1(3-phosphoinositide-dependent protein kinase-1,PDK-1)的研究主要集中在内分泌和肿瘤学等学科领域,在骨科学中关于其对成骨分化的影响尚未有系统研究与报道。目的:通过使用稳定表达cre酶的腺...背景:国内外对于3-磷酸肌醇依赖蛋白激酶1(3-phosphoinositide-dependent protein kinase-1,PDK-1)的研究主要集中在内分泌和肿瘤学等学科领域,在骨科学中关于其对成骨分化的影响尚未有系统研究与报道。目的:通过使用稳定表达cre酶的腺病毒(pHBAd-cre-EGFP)转染PDK-1^(flox/flox)小鼠骨髓间充质干细胞,观察PDK-1在成骨细胞分化中的作用。方法:体外培养获得来源于纯合子PDK-1^(flox/flox)小鼠的骨髓间充质干细胞,设立对照组、空载病毒组(pHBAd-EGFP)和pHBAd-cre-EGFP组,对照组仅用成骨细胞诱导培养基诱导培养骨髓间充质干细胞,空载病毒组使用pHBAd-EGFP转染骨髓间充质干细胞,pHBAd-cre-EGFP组使用含Cre重组酶的重组腺病毒(pHBAd-cre-EGFP)干扰骨髓间充质干细胞中的PDK-1基因,然后进行成骨诱导,采用碱性磷酸酶染色、碱性磷酸酶活性、茜素红染色和qPCR检测成骨相关基因表达来评价各组成骨细胞的分化成熟情况。结果与结论:pHBAd-cre-EGFP组细胞的碱性磷酸酶分泌、碱性磷酸酶活性、矿化能力均明显低于其他2组(P<0.05,P<0.01),成骨细胞相关基因Runx2、骨钙素和Ⅰ型胶原的表达也明显低于其他2组(P<0.01)。结果表明,体外干扰PDK-1基因表达可显著抑制骨髓间充质干细胞成骨分化。展开更多
Recent evidence of research has been proposed that the phosphoinositide 3-kinase(PI3K) pathway is noticeable target for searching novel anticancer agents. The phosphoinositide 3-kinase(PI3K) is accountable for harmoni...Recent evidence of research has been proposed that the phosphoinositide 3-kinase(PI3K) pathway is noticeable target for searching novel anticancer agents. The phosphoinositide 3-kinase(PI3K) is accountable for harmonizing a diverse range of cell functions, such as transcription, proliferation, cell survival, cell growth, degranulation, vesicular trafficking and cell migration, which are mostly involved in carcinogenesis. Particularly, PI3K-mediated signaling molecules and its effects on gene expression contribute to tumorigenesis. PI3Ks generally are grouped into three distinct classes: Ⅰ, Ⅱ and Ⅲ according to their structure and function. The class IA of PI3K includes an alpha, beta or delta p110 catalytic subunit(p110α, p110β, or p110γ), which are associated with the activation of RTKs. Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K, have just been recognized as novel mechanisms of inducing oncogenic PI3K signaling. Therefore, the class IA PI3K is the only one of most evidently implicated in cancer. The PI3K pathway is mostly mutated in more cancer patients compared with normal person, making it an eyecatching molecular target for analyses based on inhibitor molecule. In this article, we highlighted the signaling effects and regulation pathway of PI3K involved in the development and survival of tumor cells. The consequence and intricacy of PI3K pathway made it an essential beneficial target for cancer treatment.展开更多
文摘Phosphoinositide-dependent protein kinase-1 (PDK1), the class of serine threonine kinase, is a master regulator of the AGC family of kinases. It is a main component of the PI3K pathway. As it is reported that this pathway is most commonly, and this pathway is the most commonly deregulated among many cancers. So designing a selective inhibitor of PDK1 may have the efficacy as an anticancer agent. Herein, we describe our work focused on the structure based on screening of 95% similar analogues of Myricetin deposited in PubChem database as earlier studies have been suggested that myricetin acts as an anti cancer agent. Further molecular docking as well as the in silico ADMET studies are incorporated on these compounds to evaluate the binding and pharmacokinetic properties of these compounds. Due to low oral bioavailability, clinical use of myricetin is limited. Therefore this study is an attempt towards screening of structurally similar better compounds as compare with myricetin which can act as better inhibitor against PDK-1.
文摘背景:国内外对于3-磷酸肌醇依赖蛋白激酶1(3-phosphoinositide-dependent protein kinase-1,PDK-1)的研究主要集中在内分泌和肿瘤学等学科领域,在骨科学中关于其对成骨分化的影响尚未有系统研究与报道。目的:通过使用稳定表达cre酶的腺病毒(pHBAd-cre-EGFP)转染PDK-1^(flox/flox)小鼠骨髓间充质干细胞,观察PDK-1在成骨细胞分化中的作用。方法:体外培养获得来源于纯合子PDK-1^(flox/flox)小鼠的骨髓间充质干细胞,设立对照组、空载病毒组(pHBAd-EGFP)和pHBAd-cre-EGFP组,对照组仅用成骨细胞诱导培养基诱导培养骨髓间充质干细胞,空载病毒组使用pHBAd-EGFP转染骨髓间充质干细胞,pHBAd-cre-EGFP组使用含Cre重组酶的重组腺病毒(pHBAd-cre-EGFP)干扰骨髓间充质干细胞中的PDK-1基因,然后进行成骨诱导,采用碱性磷酸酶染色、碱性磷酸酶活性、茜素红染色和qPCR检测成骨相关基因表达来评价各组成骨细胞的分化成熟情况。结果与结论:pHBAd-cre-EGFP组细胞的碱性磷酸酶分泌、碱性磷酸酶活性、矿化能力均明显低于其他2组(P<0.05,P<0.01),成骨细胞相关基因Runx2、骨钙素和Ⅰ型胶原的表达也明显低于其他2组(P<0.01)。结果表明,体外干扰PDK-1基因表达可显著抑制骨髓间充质干细胞成骨分化。
文摘Recent evidence of research has been proposed that the phosphoinositide 3-kinase(PI3K) pathway is noticeable target for searching novel anticancer agents. The phosphoinositide 3-kinase(PI3K) is accountable for harmonizing a diverse range of cell functions, such as transcription, proliferation, cell survival, cell growth, degranulation, vesicular trafficking and cell migration, which are mostly involved in carcinogenesis. Particularly, PI3K-mediated signaling molecules and its effects on gene expression contribute to tumorigenesis. PI3Ks generally are grouped into three distinct classes: Ⅰ, Ⅱ and Ⅲ according to their structure and function. The class IA of PI3K includes an alpha, beta or delta p110 catalytic subunit(p110α, p110β, or p110γ), which are associated with the activation of RTKs. Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K, have just been recognized as novel mechanisms of inducing oncogenic PI3K signaling. Therefore, the class IA PI3K is the only one of most evidently implicated in cancer. The PI3K pathway is mostly mutated in more cancer patients compared with normal person, making it an eyecatching molecular target for analyses based on inhibitor molecule. In this article, we highlighted the signaling effects and regulation pathway of PI3K involved in the development and survival of tumor cells. The consequence and intricacy of PI3K pathway made it an essential beneficial target for cancer treatment.
